Do patients at high risk of nonsudden cardiac death benefit from prophylactic ICD therapy?

Current Opinion in Cardiology

Volumn 27, Issue 1, 2012, Pages 1-7

  Scott, Paul A ^a   Sterns, Laurence D ^a   Tang, Anthony S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

heart failure; implantable cardioverter defibrillator; sudden cardiac death

Indexed keywords

CARDIOVASCULAR RISK; COMORBIDITY; DEFIBRILLATOR; DEVICE THERAPY; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; NONSUDDEN CARDIAC DEATH; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL;

AGE FACTORS; CARDIAC OUTPUT, LOW; COMORBIDITY; DEFIBRILLATORS, IMPLANTABLE; HEART ARREST; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; STROKE VOLUME; UNCERTAINTY;

EID: 83055170878     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32834d84bf     Document Type: Review

References (31)

1. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary. Heart Rhythm 2008; 5:934-955.
2. Levy WC, Lee KL, Hellkamp AS, et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009; 120:835-842.
3. Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 51:288-296.
4. Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007; 116:392-398. (Pubitemid 47196544)
5. Poole-Wilson PA, Uretsky BF, Thygesen K, et al. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003; 89:42-48. (Pubitemid 36044288)
6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
7. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481-2488. (Pubitemid 39603155)
8. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009; 361:1427-1436.
9. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008; 52:1111-1121.
10. Al-Khatib SM, Hellkamp A, Curtis J, et al. Non-evidence-based ICD implantations in the United States. JAMA 2011; 305:43-49.
11. Theuns DAMJ, Smith T, Hunink MGM, et al. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or nonischaemic heart disease: a systematic review and meta-analysis. Europace 2010; 12:1564-1570.
12. Swindle JP, Rich MW, McCann P, et al. Implantable cardiac device procedures in older patients: use and in-hospital outcomes. Arch Intern Med 2010; 170:631-637.
13. Buxton AE, Ellison KE, Lorvidhaya P, Ziv O. Left ventricular ejection fraction for sudden death risk stratification and guiding implantable cardioverterdefibrillators implantation. J Cardiovasc Pharmacol 2010; 55:450-455.
14. Makikallio TH, Barthel P, Schneider R, et al. Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment era. Eur Heart J 2005; 26:762-769. (Pubitemid 40547078)
15. Buxton AE, Lee KL, Hafley GE, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT Study. J Am Coll Cardiol 2007; 50:1150-1157. (Pubitemid 47375017)
16. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 29:2388-2442.
17. Yamokoski LM, Hasselblad V, Moser DK, et al. Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE Trial. J Cardiac Fail 2007; 13:8-13. (Pubitemid 46330838)
18. Krahn AD, Connolly SJ, Roberts RS, Gent M. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J 2004; 147:837-840. (Pubitemid 38880994)
19. Santangeli P, Di Biase L, Dello Russo A, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med 2010; 153:592-599.
20. Epstein AE, Kay GN, Plumb VJ, et al. Implantable cardioverter- defibrillator prescription in the elderly. Heart Rhythm 2009; 6:1136-1143.
21. Pellegrini CN, Lee K, Olgin JE, et al. Impact of advanced age on survival in patients with implantable cardioverter defibrillators. Europace 2008; 10:1296-1301.
22. Clarke B, Howlett J, Sapp J, et al. The effect of comorbidity on the competing risk of sudden and nonsudden death in an ambulatory heart failure population. Can J Cardiol 2011; 27:254-261.
23. Lee DS, Tu JV, Austin PC, et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 2007; 49:2408-2415. (Pubitemid 46962260)
24. Theuns DA, Schaer BA, Soliman OI, et al. The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. Europace 2011; 13:62-69.
25. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113:671-678.
26. Goldenberg I, Moss AJ, McNitt S, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006; 98:485-490. (Pubitemid 44162874)
27. Korantzopoulos P, Liu T, Li L, et al. Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis. Europace 2009; 11: 1469-1475.
28. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113:1424-1433. (Pubitemid 43739439)
29. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681-689. (Pubitemid 30167025)
30. Cleland JGF, Daubert J-C, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27:1928-1932. (Pubitemid 44297365)
31. Efficacy of implantable defibrillator therapy after a myocardial infarction (REFINE-ICD). www.clinicaltrials.gov. Identifier NCT00673842.